Approaches to erythrocyte-mediated drug delivery

Bibliography

• Juliano R, Poste G, Tomlinson E. Perspective from the founding editors. Preface. Adv Drug Deliv Rev 2013;65:3-4
   PubMed Web of Science ®Google Scholar
• Mullertz A, Ogbonna A, Ren S, et al. New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs. J Pharm Pharmacol 2010;62:1622-36
   PubMed Web of Science ®Google Scholar
• Schafroth N, Arpagaus C, Jadhav UY, et al. Nano and microparticle engineering of water insoluble drugs using a novel spray-drying process. Colloids Surf B Biointerfaces 2012;90:8-15
   PubMed Web of Science ®Google Scholar
• Williams HD, Trevaskis NL, Charman SA, et al. Strategies to address low drug solubility in discovery and development. Pharmacol Rev 2013;65:315-499
   PubMed Web of Science ®Google Scholar
• Alam MA, Ali R, Al-Jenoobi FI, et al. Solid dispersions: a strategy for poorly aqueous soluble drugs and technology updates. Expert Opin Drug Deliv 2012;9:1419-40
   PubMed Web of Science ®Google Scholar
• Lim SB, Banerjee A, Onyuksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J Control Release 2012;163:34-45
   PubMed Web of Science ®Google Scholar
• Sun H, Meng F, Cheng R, et al. Reduction-sensitive degradable micellar nanoparticles as smart and intuitive delivery systems for cancer chemotherapy. Expert Opin Drug Deliv 2013;10:1109-22
   PubMed Web of Science ®Google Scholar
• Pohlmann AR, Fonseca FN, Paese K, et al. Poly(-caprolactone) microcapsules and nanocapsules in drug delivery. Expert Opin Drug Deliv 2013;10:623-38
   PubMed Web of Science ®Google Scholar
• Kuthati Y, Sung PJ, Weng CF, et al. Functionalization of mesoporous silica nanoparticles for targeting, biocompatibility, combined cancer therapies and theragnosis. J Nanosci Nanotechnol 2013;13:2399-430
   PubMed Web of Science ®Google Scholar
• Chacko AM, Li C, Pryma DA, et al. Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood-brain barrier divide. Expert Opin Drug Deliv 2013;10:907-26
   PubMed Web of Science ®Google Scholar
• Dufes C, Al RM, Somani S. Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells. Ther Deliv 2013;4:629-40
   PubMedGoogle Scholar
• Seedial SM, Ghosh S, Saunders RS, et al. Local drug delivery to prevent restenosis. J Vasc Surg 2013;57:1403-14
   PubMed Web of Science ®Google Scholar
• Pierige F, Serafini S, Rossi L, et al. Cell-based drug delivery. Adv Drug Deliv Rev 2008;60:286-95
   PubMed Web of Science ®Google Scholar
• Rossi L, Serafini S, Pierige F, et al. Erythrocyte-based drug delivery. Expert Opin Drug Deliv 2005;2:311-22
   PubMedGoogle Scholar
• Biagiotti S, Paoletti MF, Fraternale A, et al. Drug delivery by red blood cells. IUBMB Life 2011;63:621-31
   PubMed Web of Science ®Google Scholar
• Magnani M, Pierige F, Rossi L. Erythrocytes as a novel delivery vehicle for biologics: from enzymes to nucleic acid-based therapeutics. Ther Deliv 2012;3:405-14
   PubMedGoogle Scholar
• Muzykantov VR. Drug delivery by red blood cells: vascular carriers designed by mother nature. Expert Opin Drug Deliv 2010;7:403-27
   PubMed Web of Science ®Google Scholar
• Carnemolla R, Muzykantov VR. Vascular targeting of antithrombotic agents. IUBMB Life 2011;63:632-9
   PubMed Web of Science ®Google Scholar
• Muzykantov VR. Drug delivery carriers on the fringes: natural red blood cells versus synthetic multilayered capsules. Expert Opin Drug Deliv 2013;10:1-4
   PubMed Web of Science ®Google Scholar
• Greineder CF, Howard MD, Carnemolla R, et al. Advanced drug delivery systems for antithrombotic agents. Blood 2013;122:1565-75
   PubMed Web of Science ®Google Scholar
• Antonelli A, Sfara C, Battistelli S, et al. New strategies to prolong the in vivo life span of iron-based contrast agents for MRI. PLoS One 2013;8:e78542
   PubMed Web of Science ®Google Scholar
• Antonelli A, Sfara C, Rahmer J, et al. Red blood cells as carriers in magnetic particle imaging. Biomed Tech (Berl) 2013;58:517-25
   PubMed Web of Science ®Google Scholar
• Antonelli A, Sfara C, Manuali E, et al. Encapsulation of superparamagnetic nanoparticles into red blood cells as new carriers of MRI contrast agents. Nanomedicine (Lond) 2011;6:211-23
   PubMed Web of Science ®Google Scholar
• Markov DE, Boeve H, Gleich B, et al. Human erythrocytes as nanoparticle carriers for magnetic particle imaging. Phys Med Biol 2010;55:6461-73
   PubMed Web of Science ®Google Scholar
• Rahmer J, Antonelli A, Sfara C, et al. Nanoparticle encapsulation in red blood cells enables blood-pool magnetic particle imaging hours after injection. Phys Med Biol 2013;58:3965-77
   PubMed Web of Science ®Google Scholar
• Flower R, Peiretti E, Magnani M, et al. Observation of erythrocyte dynamics in the retinal capillaries and choriocapillaris using ICG-loaded erythrocyte ghost cells. Invest Ophthalmol Vis Sci 2008;49:5510-16
   PubMed Web of Science ®Google Scholar
• Antonelli A, Sfara C, Mosca L, et al. New biomimetic constructs for improved in vivo circulation of superparamagnetic nanoparticles. J Nanosci Nanotechnol 2008;8:2270-8
   PubMed Web of Science ®Google Scholar
• Rossi L, Serafini S, Cenerini L, et al. Erythrocyte-mediated delivery of dexamethasone in patients with chronic obstructive pulmonary disease. Biotechnol Appl Biochem 2001;33:85-9
   PubMed Web of Science ®Google Scholar
• Rossi L, Castro M, D'Orio F, et al. Low doses of dexamethasone constantly delivered by autologous erythrocytes slow the progression of lung disease in cystic fibrosis patients. Blood Cells Mol Dis 2004;33:57-63
   PubMed Web of Science ®Google Scholar
• Annese V, Latiano A, Rossi L, et al. Erythrocytes-mediated delivery of dexamethasone in steroid-dependent IBD patients-a pilot uncontrolled study. Am J Gastroenterol 2005;100:1370-5
   PubMed Web of Science ®Google Scholar
• Castro M, Knafelz D, Rossi L, et al. Periodic treatment with autologous erythrocytes loaded with dexamethasone 21-phosphate for fistulizing pediatric Crohn's disease: case report. J Pediatr Gastroenterol Nutr 2006;42:313-15
   PubMed Web of Science ®Google Scholar
• Annese V, Latiano A, Rossi L, et al. The polymorphism of multi-drug resistance 1 gene (MDR1) does not influence the pharmacokinetics of dexamethasone loaded into autologous erythrocytes of patients with inflammatory bowel disease. Eur Rev Med Pharmacol Sci 2006;10:27-31
   PubMedGoogle Scholar
• Castro M, Rossi L, Papadatou B, et al. Long-term treatment with autologous red blood cells loaded with dexamethasone 21-phosphate in pediatric patients affected by steroid-dependent Crohn disease. J Pediatr Gastroenterol Nutr 2007;44:423-6
   PubMed Web of Science ®Google Scholar
• Bossa F, Annese V, Valvano MR, et al. Erythrocytes-mediated delivery of dexamethasone 21-phosphate in steroid-dependent ulcerative colitis: a randomized, double-blind Sham-controlled study. Inflamm Bowel Dis 2013;19:1872-9
   PubMed Web of Science ®Google Scholar
• Bossa F, Latiano A, Rossi L, et al. Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. Am J Gastroenterol 2008;103:2509-16
   PubMed Web of Science ®Google Scholar
• Chessa L, Leuzzi V, Plebani A, et al. Intra-erythrocyte infusion of dexamethasone reduces neurological symptoms in ataxia teleangiectasia patients: results of a phase 2 trial. Orphanet J Rare Dis 2014;9:5
   PubMed Web of Science ®Google Scholar
• Lucidi V, Tozzi AE, Bella S, et al. A pilot trial on safety and efficacy of erythrocyte-mediated steroid treatment in CF patients. BMC Pediatr 2006;6:17
   PubMedGoogle Scholar
• Pierige F, De MC, Orlotti N, et al. Cytotoxic activity of 2-Fluoro-ara-AMP and 2-Fluoro-ara-AMP-loaded erythrocytes against human breast carcinoma cell lines. Int J Oncol 2010;37:133-42
   PubMed Web of Science ®Google Scholar
• Fraternale A, Rossi L, Magnani M. Encapsulation, metabolism and release of 2-fluoro-ara-AMP from human erythrocytes. Biochim Biophys Acta 1996;1291:149-54
   PubMed Web of Science ®Google Scholar
• Magnani M, Bianchi M, Rossi L, et al. Human red blood cells as bioreactors for the release of 2',3'-dideoxycytidine, an inhibitor of HIV infectivity. Biochem Biophys Res Commun 1989;164:446-52
   PubMed Web of Science ®Google Scholar
• Solimano F, Bischi GI, Bianchi M, et al. A nonlinear three-compartment model for the administration of 2′,3′-dideoxycytidine by using red blood cells as bioreactors. Bull Math Biol 1990;52:785-96
   PubMed Web of Science ®Google Scholar
• Benatti U, Giovine M, Damonte G, et al. Azidothymidine homodinucleotide-loaded erythrocytes and bioreactors for slow delivery of the antiretroviral drug azidothymidine. Biochem Biophys Res Commun 1996;220:20-5
   PubMed Web of Science ®Google Scholar
• Rossi L, Brandi G, Schiavano GF, et al. Heterodimer-loaded erythrocytes as bioreactors for slow delivery of the antiviral drug azidothymidine and the antimycobacterial drug ethambutol. AIDS Res Hum Retroviruses 1999;15:345-53
   PubMed Web of Science ®Google Scholar
• Ihler GM, Glew RH, Schnure FW. Enzyme loading of erythrocytes. Proc Natl Acad Sci USA 1973;70:2663-6
   PubMed Web of Science ®Google Scholar
• Dale GL, Beutler E. Enzyme replacement therapy in Gaucher's disease: a rapid, high-yield method for purification of glucocerebrosidase. Proc Natl Acad Sci USA 1976;73:4672-4
   PubMed Web of Science ®Google Scholar
• Beutler E, Dale GL, Guinto DE, et al. Enzyme replacement therapy in Gaucher's disease: preliminary clinical trial of a new enzyme preparation. Proc Natl Acad Sci USA 1977;74:4620-3
   PubMed Web of Science ®Google Scholar
• Bax BE, Bain MD, Fairbanks LD, et al. In vitro and in vivo studies with human carrier erythrocytes loaded with polyethylene glycol-conjugated and native adenosine deaminase. Br J Haematol 2000;109:549-54
   PubMed Web of Science ®Google Scholar
• Bax BE, Bain MD, Fairbanks LD, et al. A 9-yr evaluation of carrier erythrocyte encapsulated adenosine deaminase (ADA) therapy in a patient with adult-type ADA deficiency. Eur J Haematol 2007;79:338-48
   PubMed Web of Science ®Google Scholar
• Moran NF, Bain MD, Muqit MM, et al. Carrier erythrocyte entrapped thymidine phosphorylase therapy for MNGIE. Neurology 2008;71:686-8
   PubMed Web of Science ®Google Scholar
• Bax BE, Bain MD, Scarpelli M, et al. Clinical and biochemical improvements in a patient with MNGIE following enzyme replacement. Neurology 2013;81:1269-71
   PubMed Web of Science ®Google Scholar
• Agrawal V, Woo JH, Borthakur G, et al. Red blood cell-encapsulated L-asparaginase: potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia. Protein Pept Lett 2013;20:392-402
   PubMed Web of Science ®Google Scholar
• Domenech C, Thomas X, Chabaud S, et al. l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. Br J Haematol 2011;153:58-65
   PubMed Web of Science ®Google Scholar
• Kwon YM, Chung HS, Moon C, et al. L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL). J Control Release 2009;139:182-9
   PubMed Web of Science ®Google Scholar
• Favretto ME, Cluitmans JC, Bosman GJ, et al. Human erythrocytes as drug carriers: loading efficiency and side effects of hypotonic dialysis, chlorpromazine treatment and fusion with liposomes. J Control Release 2013;170:343-51
   PubMed Web of Science ®Google Scholar
• Bax BE, Bain MD, Talbot PJ, et al. Survival of human carrier erythrocytes in vivo. Clin Sci (Lond) 1999;96:171-8
   PubMed Web of Science ®Google Scholar
• Magnani M, Rossi L, Fraternale A, et al. Targeting antiviral nucleotide analogues to macrophages. J Leukoc Biol 1997;62:133-7
   PubMed Web of Science ®Google Scholar
• Magnani M, Rossi L, Brandi G, et al. Targeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: in vitro and in vivo studies. Proc Natl Acad Sci USA 1992;89:6477-81
   PubMed Web of Science ®Google Scholar
• Rossi L, Brandi G, Fraternale A, et al. Inhibition of murine retrovirus-induced immunodeficiency disease by dideoxycytidine and dideoxycytidine 5'-triphosphate. J Acquir Immune Defic Syndr 1993;6:1179-86
   PubMed Web of Science ®Google Scholar
• Magnani M, Rossi L, Fraternale A, et al. Feline immunodeficiency virus infection of macrophages: in vitro and in vivo inhibition by dideoxycytidine-5'-triphosphate-loaded erythrocytes. AIDS Res Hum Retroviruses 1994;10:1179-86
   PubMed Web of Science ®Google Scholar
• Chiarantini L, Rossi L, Fraternale A, et al. Modulated red blood cell survival by membrane protein clustering. Mol Cell Biochem 1995;144:53-9
   PubMed Web of Science ®Google Scholar
• Rossi L, Serafini S, Antonelli A, et al. Macrophage depletion induced by clodronate-loaded erythrocytes. J Drug Target 2005;13:99-111
   PubMed Web of Science ®Google Scholar
• Rossi L, Migliavacca B, Pierige F, et al. Prolonged islet allograft survival in diabetic mice upon macrophage depletion by clodronate-loaded erythrocytes. Transplantation 2008;85:648-50
   PubMed Web of Science ®Google Scholar
• Chow FS, Piekoszewski W, Jusko WJ. Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion. Drug Metab Dispos 1997;25:610-16
   PubMed Web of Science ®Google Scholar
• Walensky LD, Gascard P, Fields ME, et al. The 13-kD FK506 binding protein, FKBP13, interacts with a novel homologue of the erythrocyte membrane cytoskeletal protein 4.1. J Cell Biol 1998;141:143-53
   PubMed Web of Science ®Google Scholar
• Foxwell BM, Frazer G, Winters M, et al. Identification of cyclophilin as the erythrocyte ciclosporin-binding protein. Biochim Biophys Acta 1988;938:447-55
   PubMed Web of Science ®Google Scholar
• Reichel C, von Falkenhausen M, Brockmeier D, et al. Characterization of cyclosporine A uptake in human erythrocytes. Eur J Clin Pharmacol 1994;46:417-19
   PubMed Web of Science ®Google Scholar
• Biagiotti S, Rossi L, Bianchi M, et al. Immunophilin-loaded erythrocytes as a new delivery strategy for immunosuppressive drugs. J Control Release 2011;154:306-13
   PubMed Web of Science ®Google Scholar
• Sudlow G, Birkett DJ, Wade DN. Further characterization of specific drug binding sites on human serum albumin. Mol Pharmacol 1976;12:1052-61
   PubMed Web of Science ®Google Scholar
• Ghuman J, Zunszain PA, Petitpas I, et al. Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol 2005;353:38-52
   PubMed Web of Science ®Google Scholar
• Hamidi M, Azimi K, Mohammadi-Samani S. Co-encapsulation of a drug with a protein in erythrocytes for improved drug loading and release: phenytoin and bovine serum albumin (BSA). J Pharm Pharm Sci 2011;14:46-59
   PubMed Web of Science ®Google Scholar
• Muzykantov VR, Murciano JC, Taylor RP, et al. Regulation of the complement-mediated elimination of red blood cells modified with biotin and streptavidin. Anal Biochem 1996;241:109-19
   PubMed Web of Science ®Google Scholar
• Murciano JC, Medinilla S, Eslin D, et al. Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes. Nat Biotechnol 2003;21:891-6
   PubMed Web of Science ®Google Scholar
• Ganguly K, Krasik T, Medinilla S, et al. Blood clearance and activity of erythrocyte-coupled fibrinolytics. J Pharmacol Exp Ther 2005;312:1106-13
   PubMed Web of Science ®Google Scholar
• Ganguly K, Goel MS, Krasik T, et al. Fibrin affinity of erythrocyte-coupled tissue-type plasminogen activators endures hemodynamic forces and enhances fibrinolysis in vivo. J Pharmacol Exp Ther 2006;316:1130-6
   PubMed Web of Science ®Google Scholar
• Danielyan K, Ganguly K, Ding BS, et al. Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator. Circulation 2008;118:1442-9
   PubMed Web of Science ®Google Scholar
• Stein SC, Ganguly K, Belfield CM, et al. Erythrocyte-bound tissue plasminogen activator is neuroprotective in experimental traumatic brain injury. J Neurotrauma 2009;26:1585-92
   PubMed Web of Science ®Google Scholar
• Pisapia JM, Xu X, Kelly J, et al. Microthrombosis after experimental subarachnoid hemorrhage: time course and effect of red blood cell-bound thrombin-activated pro-urokinase and clazosentan. Exp Neurol 2012;233:357-63
   PubMed Web of Science ®Google Scholar
• Armstead WM, Ganguly K, Kiessling JW, et al. Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK activation. J Cereb Blood Flow Metab 2009;29:1463-74
   PubMed Web of Science ®Google Scholar
• Armstead WM, Ganguly K, Riley J, et al. Red blood cell-coupled tissue plasminogen activator prevents impairment of cerebral vasodilatory responses through inhibition of c-Jun-N-terminal kinase and potentiation of p38 mitogen-activated protein kinase after cerebral photothrombosis in the newborn pig. Pediatr Crit Care Med 2011;12:e369-75
   PubMed Web of Science ®Google Scholar
• Zaitsev S, Danielyan K, Murciano JC, et al. Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis. Blood 2006;108:1895-902
   PubMed Web of Science ®Google Scholar
• Zaitsev S, Spitzer D, Murciano JC, et al. Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis. J Pharmacol Exp Ther 2010;332:1022-31
   PubMed Web of Science ®Google Scholar
• Zaitsev S, Spitzer D, Murciano JC, et al. Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation. Blood 2010;115:5241-8
   PubMed Web of Science ®Google Scholar